First patient dosed with Yuhan’s degenerative disc drug

By | translator Alice Kang

22.08.25 11:31:00

가나다라 0

YH14618, which was licensed out to US firm Spine BioPharma, enters Phase III trial

Phase III trial initiated in 400 patients in the US… result to be disclosed by 2024

Company receives ₩2.7 billion as royalty

Yuhan Corp (President/CEO: Wook-Je Cho) announced on the 25th that the first patient was dosed with its new degenerative disc drug, “YH14618(SB-01, Remedisc).”

The clinical trial was led by the US pharmaceutical company Spine BioPharma on 400 degenerative disc patients at 30 clinical sites in the US.

The Phase III trial was conducted to evaluate the improvement in persistent pain and other related disorders and the safety of YH14618 for 6 months after initial intradiscal injection. With a 12-month follow-up period, the results of the Phase III trial are expected to be secured by 2024.

Yuhan Corp received the license for YH14618 from Ensol Biosciences in 2009 for domesti

(same@dailypharm.com)

If you want to see the full article, please JOIN US (click)